Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference
Back to Newsroom
Mentioned in this Article

Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference

Thursday, August 5, 2021 8:00 AM
Share this article now
Topic:
Conferences

MINNEAPOLIS, MN / ACCESSWIRE / August 5, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced its participation in the Canaccord Genuity 41st Annual Growth Conference to be held August 10-12, 2021. Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, is scheduled to present in a virtual fireside chat at 8:30 a.m. ET on Thursday, August 12, 2021.

A live webcast of the fireside chat will be available at: https://wsw.com/webcast/canaccord60/celc/2404732. Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://celcuity.com/investors/events-webcasts/ with a replay available shortly after the live event.

About Celcuity

Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated companion diagnostic and therapeutic strategy. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Its therapeutic efforts are focused on in-licensing and developing molecularly targeted therapies that address the same cancer driver its companion diagnostics can identify. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com.

Contacts:

Celcuity Inc.
Brian Sullivan, [email protected]
Vicky Hahne, [email protected]
763-392-0123

Westwicke ICR
Robert Uhl, [email protected]
(619) 228-5886

SOURCE: Celcuity Inc. 

Celcuity Inc.
Back to Newsroom
{{msgBox.title}}

that

Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions